search
Back to results

NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

Primary Purpose

Overweight or Obesity

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
NDPP-NextGen
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Overweight or Obesity focused on measuring Body mass index, Pre-conception, Diabetes Mellitus, Diet, Gestational diabetes, Neonatal adiposity, Maternal and Child Health, Overweight, Obese, Pregnancy, Randomized Control Trial, Weight, adverse maternal outcomes, Diabetes Prevention Program, glucose, gestational weight gain, lifestyle intervention, usual care, remote delivery, young women

Eligibility Criteria

18 Years - 39 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Established patient at Denver Health Biologically female (inclusive of all gender identities) Aged 18-39 years English- or Spanish-speaking BMI ≥25 kg/m2 (≥23 kg/m2 if Asian race) Activities that lead to pregnancy in past 3 months Interested in pregnancy within 24 months, including: High interest (actively trying to conceive) General interest (not actively trying but wanting to become pregnant in the foreseeable future) Neutral interest (not planning pregnancy or using contraception for religious reasons) Exclusion Criteria: Currently pregnant Non-gestational diabetes (type 1, type 2) Long-acting contraceptives (intrauterine device, implant, injection) with plans to continue for >1 year (barrier & short-acting hormonal contraception permitted given ease of discontinuing to facilitate pregnancy) Medical procedures (e.g., tubal ligation, hysterectomy) or conditions that impede pregnancy (e.g., polycystic ovarian syndrome) Documented infertility or unsuccessfully trying to conceive for ≥12 months Prior participation in the NDPP

Sites / Locations

  • University of Colorado Anschutz Medical CampusRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Healthy Lifestyle

Healthy Women

Arm Description

Women in the Healthy Lifestyle group will be invited to attend the online NDPP-NextGen class which will cover how to eat healthy, be active, and lose weight before getting pregnant. The classes will be led by a trained Lifestyle Coach. Each class lasts about 1 hour. Classes initially meet about once a week (for the first 6 months), then twice a month (for the next 3 months), and then once a month (for the last 3 months). Classes will meet virtually through video-conference. Lifestyle coaches will also call participants in between classes to discuss how participants are doing, answer questions, and provide reminders for upcoming classes. Prior to the first class, women will also participate in a "pre-session" designed to increase NDPP engagement via discussion of diabetes risks and treatment options (i.e., clarify relevance) and motivational interviewing to resolve barriers.

Women in the Healthy Women group get a packet of information standardly given in OB clinics about how to be healthy before, during and after pregnancy.

Outcomes

Primary Outcome Measures

BMI in early pregnancy
Height and weight will be measured and combined to report BMI at the post-conception research visit occurring at 6-8 weeks gestation.

Secondary Outcome Measures

Glycemia in early pregnancy
Fasting glucose

Full Information

First Posted
November 21, 2022
Last Updated
April 27, 2023
Sponsor
University of Colorado, Denver
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
search

1. Study Identification

Unique Protocol Identification Number
NCT05674799
Brief Title
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
Official Title
NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 8, 2023 (Actual)
Primary Completion Date
May 31, 2027 (Anticipated)
Study Completion Date
May 31, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this clinical trial is to test an enhanced version of the National Diabetes Prevention Program (NDPP-NextGen) that is tailored to young women in childbearing years. The investigators will recruit 360 women aged 18-39 years with overweight/obesity who are not currently pregnant, but likely to conceive within 24 months. Women will be randomized to NDPP-NextGen or a usual care control group. The NDPP-NextGen group will participate in the adapted NDPP online group class across 12 months, and the control group will get a packet of information about how to be healthy before, during and after pregnancy. The main goals of the study are: to assess effects of NDPP-NextGen on pre-pregnancy blood sugar and early pregnancy BMI to assess effects of NDPP-NextGen on weight gain and behavioral outcomes during pregnancy to explore effects of NDPP-NextGen on infant's percentage of fat tissue at birth All participants will complete up to 4 research visits: baseline, conception, mid-pregnancy, and delivery. These visits will include: Questionnaires about health, diet, activity, smoking, self-confidence, and depression Body size measurements Fasted blood draws Participants will also be asked to weigh themselves weekly using home scales that are connected to the research database. At the delivery visit, investigators will measure the baby's body size and collect a cord blood sample.
Detailed Description
Intrauterine exposure to maternal overweight/obesity and diabetes transmits risks to offspring, triggering a disease cycle across generations. Over half of US women have overweight or obesity at conception and ~10% of pregnancies are affected by diabetes, exposing nearly 2 million infants each year. Prenatal lifestyle interventions are well-studied, yet begin too late to impact the critical period of conception and early pregnancy. Starting interventions before conception may be key to halting the disease cycle. However, prior research is limited, often lacks offspring outcomes (especially sensitive measures), includes mostly white and affluent participants, and has been challenged to identify women likely to conceive soon. Further research is needed on scalable strategies to improve maternal-child health during preconception and early pregnancy, especially for racial and ethnic minority or low-income women with disparately high prevalence of obesity and diabetes. The National Diabetes Prevention Program (NDPP) is a widely-disseminated lifestyle intervention to reduce weight and glycemia that has untapped potential to improve maternal-child health. From an implementation science perspective, the NDPP has greater potential impact than new interventions that are unlikely to be scaled up, even if efficacious. Denver Health has delivered the NDPP to >1600 adults since 2013, including >350 young women. Preliminary data shows that the NDPP may reduce peri-conceptional risks in diverse, low-income women. While limited engagement by younger women in the NDPP is a concern, strategies to increase engagement (motivational "pre-sessions", remote delivery, and classes specially for young women) are promising. For example, young women attended the 12-month NDPP for 64 days longer after receiving a pre-session, with 2.0 kg/m2 lower preconception BMI and 0.4% lower A1c in early pregnancy, than controls. To plan a preconception trial, the investigators developed a 2-step screening protocol to 1) use electronic health record data (e.g., contraceptive use) to identify women who are more likely to conceive by 24 months (36% vs. 13% for all young women), and 2) outreach to confirm current family planning to expect ≥60% conception, based on preliminary data showing that 73% conceived by 24 months if they endorsed intention to conceive or being sexual active without highly effective contraception. The investigators propose a randomized controlled trial of an enhanced NDPP (NDPP-NextGen) initiated before pregnancy to evaluate effects on maternal-child health. They will recruit 360 women aged 18-39 years with overweight/obesity who are likely to conceive within 24 months. Women will be randomized to NDPP- NextGen or a usual care control group. The specific aims are 1) to assess effects of NDPP-NextGen on peri- conceptional BMI and prenatal glycemia; 2) to assess effects of NDPP-NextGen on gestational weight gain and behavioral outcomes in pregnancy; and 3) to explore effects of NDPP-NextGen on neonatal adiposity and explanatory mechanisms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight or Obesity
Keywords
Body mass index, Pre-conception, Diabetes Mellitus, Diet, Gestational diabetes, Neonatal adiposity, Maternal and Child Health, Overweight, Obese, Pregnancy, Randomized Control Trial, Weight, adverse maternal outcomes, Diabetes Prevention Program, glucose, gestational weight gain, lifestyle intervention, usual care, remote delivery, young women

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Participants will be randomized 1:1 to a 12-month lifestyle intervention promoting healthy diet and activity to reduce body weight (NDPP-NextGen), or usual care
Masking
Outcomes Assessor
Masking Description
Professional research assistants who will be collecting data and conducting the research visits will not be told if participants are in the treatment or control group, although this may be disclosed by the participant.
Allocation
Randomized
Enrollment
360 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy Lifestyle
Arm Type
Experimental
Arm Description
Women in the Healthy Lifestyle group will be invited to attend the online NDPP-NextGen class which will cover how to eat healthy, be active, and lose weight before getting pregnant. The classes will be led by a trained Lifestyle Coach. Each class lasts about 1 hour. Classes initially meet about once a week (for the first 6 months), then twice a month (for the next 3 months), and then once a month (for the last 3 months). Classes will meet virtually through video-conference. Lifestyle coaches will also call participants in between classes to discuss how participants are doing, answer questions, and provide reminders for upcoming classes. Prior to the first class, women will also participate in a "pre-session" designed to increase NDPP engagement via discussion of diabetes risks and treatment options (i.e., clarify relevance) and motivational interviewing to resolve barriers.
Arm Title
Healthy Women
Arm Type
No Intervention
Arm Description
Women in the Healthy Women group get a packet of information standardly given in OB clinics about how to be healthy before, during and after pregnancy.
Intervention Type
Behavioral
Intervention Name(s)
NDPP-NextGen
Intervention Description
NDPP-NextGen will incorporate content on preconception/prenatal health into standard NDPP. Participants will be encouraged to make sustainable improvements in diet and activity, but without pre-set goals to better accommodate diverse, low-income populations. Upon pregnancy, recommendations will adjust to support appropriate GWG, breastfeeding, and postpartum weight loss. We will provide education on diet and activity during pregnancy/postpartum, including sufficient energy intake and exercise safety to support the growing fetus. NDPP-NextGen will include 3 strategies to better engage young women. (1) "Pre-sessions" to increase knowledge of diabetes risks, self-efficacy, and readiness to change using motivational interviewing techniques. (2) Delivering classes remotely (via phone- and video-conference) to facilitate participation regardless of inclement weather, dependent care, illness, transportation, etc. (3) Offering classes specially for young women to increase personal relevance.
Primary Outcome Measure Information:
Title
BMI in early pregnancy
Description
Height and weight will be measured and combined to report BMI at the post-conception research visit occurring at 6-8 weeks gestation.
Time Frame
6-8 weeks gestation
Secondary Outcome Measure Information:
Title
Glycemia in early pregnancy
Description
Fasting glucose
Time Frame
6-8 weeks gestation
Other Pre-specified Outcome Measures:
Title
Peri-conceptional BMI
Description
BMI at conception will be collected with cellular-enabled scales (BodyTrace®) that facilitate weekly at-home measurement to obtain weight closer to conception. Scales automatically transfer weights to a HIPAA-compliant database that is accessible only by the research team. Research staff will monitor for ≥1 transmitted weight each week, and provide prompts and assistance as needed. Investigators will average the two weights from before/after estimated date of conception to calculate approximate peri-conceptional BMI.
Time Frame
Scale data will be pulled at 6-8 weeks gestation
Title
Rate and timing of gestational weight gain (GWG)
Description
Primary method of collection will be through the use of home cellular scale weights. We will also abstract all weights from prenatal medical records as a secondary method to assess GWG. GWG will be analyzed as the difference from conception to delivery and gain within each trimester, adjusting for BMI at conception. We will also analyze GWG trajectories using linear mixed models with repeated measures drawn from the home scales and/or prenatal clinical weights. We will then classify women as having inadequate, appropriate, or excessive GWG based on BMI category, and analyze using logistic regression, again adjusting for BMI at conception.
Time Frame
Scale data will be pulled weekly from time of conception up to delivery
Title
A1C in early pregnancy
Description
Fasted blood draw
Time Frame
6-8 weeks gestation
Title
Glycemic status in early pregnancy
Description
Fasted blood draw to classify as normoglycemia, pre-diabetes, or type 2 diabetes at conception per American Diabetes Association definitions
Time Frame
6-8 weeks gestation
Title
Rate of gestational diabetes (GDM) in mid-pregnancy
Description
Abstracted from medical records
Time Frame
28-32 weeks gestation
Title
Diet quality
Description
Diet will be assessed with 24-hour dietary recalls using the Automated Self-Administered system (ASA24). This system uses the USDA multiple-pass method to query all foods and supplements consumed in the prior 24 hours and produces daily and individual food estimates for macronutrients, micronutrients, and MyPyramid Equivalents (such as servings of vegetables, fruits, whole grains, solid fats, and added sugars).
Time Frame
Baseline
Title
Diet quality
Description
Diet will be assessed with 24-hour dietary recalls using the Automated Self-Administered system (ASA24). This system uses the USDA multiple-pass method to query all foods and supplements consumed in the prior 24 hours and produces daily and individual food estimates for macronutrients, micronutrients, and MyPyramid Equivalents (such as servings of vegetables, fruits, whole grains, solid fats, and added sugars).
Time Frame
6-8 weeks gestation
Title
Diet quality
Description
Diet will be assessed with 24-hour dietary recalls using the Automated Self-Administered system (ASA24). This system uses the USDA multiple-pass method to query all foods and supplements consumed in the prior 24 hours and produces daily and individual food estimates for macronutrients, micronutrients, and MyPyramid Equivalents (such as servings of vegetables, fruits, whole grains, solid fats, and added sugars).
Time Frame
28-32 weeks gestation
Title
Physical Activity
Description
Assessed using the Pregnancy Physical Activity Questionnaire (PPAQ), while adjusting metabolic task equivalents for pregnancy. Investigators will calculate average activity intensity (sedentary to vigorous) and type (household, occupational, exercise, transportation) over the past 3 months at each collection point. Physical activity outcomes include daily minutes of sedentary, light, moderate, vigorous, household, occupational, exercise, transportation activity.
Time Frame
Baseline
Title
Physical Activity
Description
Assessed using the Pregnancy Physical Activity Questionnaire (PPAQ), while adjusting metabolic task equivalents for pregnancy. Investigators will calculate average activity intensity (sedentary to vigorous) and type (household, occupational, exercise, transportation) over the past 3 months at each collection point. Physical activity outcomes include daily minutes of sedentary, light, moderate, vigorous, household, occupational, exercise, transportation activity.
Time Frame
6-8 weeks gestation
Title
Physical Activity
Description
Assessed using the Pregnancy Physical Activity Questionnaire (PPAQ), while adjusting metabolic task equivalents for pregnancy. Investigators will calculate average activity intensity (sedentary to vigorous) and type (household, occupational, exercise, transportation) over the past 3 months at each collection point. Physical activity outcomes include daily minutes of sedentary, light, moderate, vigorous, household, occupational, exercise, transportation activity.
Time Frame
28-32 weeks gestation
Title
Smoking frequency
Description
Participants will be asked about lifetime and recent (past 6 months) usage of cigarette and marijuana. Smoking outcomes include any smoking in pregnancy (binary) and number of cigarettes (total, trimester-specific).
Time Frame
Baseline
Title
Smoking frequency
Description
Participants will be asked about lifetime and recent (past 6 months) usage of cigarette and marijuana. Smoking outcomes include any smoking in pregnancy (binary) and number of cigarettes (total, trimester-specific).
Time Frame
6-8 weeks gestation
Title
Smoking frequency
Description
Participants will be asked about lifetime and recent (past 6 months) usage of cigarette and marijuana. Smoking outcomes include any smoking in pregnancy (binary) and number of cigarettes (total, trimester-specific).
Time Frame
28-32 weeks gestation
Title
Weight management self-efficacy
Description
Assessed with the Weight Efficacy Lifestyle Questionnaire-Short Form (WEL-SF) on current confidence with weight management around negative emotions, availability, social pressure, physical discomfort, and positive activities. Weight management self-efficacy is a single score derived from the 8-item short form (range 0-72).
Time Frame
Baseline
Title
Weight management self-efficacy
Description
Assessed with the Weight Efficacy Lifestyle Questionnaire-Short Form (WEL-SF) on current confidence with weight management around negative emotions, availability, social pressure, physical discomfort, and positive activities. Weight management self-efficacy is a single score derived from the 8-item short form (range 0-72).
Time Frame
6-8 weeks gestation
Title
Weight management self-efficacy
Description
Assessed with the Weight Efficacy Lifestyle Questionnaire-Short Form (WEL-SF) on current confidence with weight management around negative emotions, availability, social pressure, physical discomfort, and positive activities. Weight management self-efficacy is a single score derived from the 8-item short form (range 0-72).
Time Frame
28-32 weeks gestation
Title
Rate of miscarriages
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of stillbirths
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of fetal deaths
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of pre-term births
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of pregnancy-induced hypertension
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of pre-eclampsia
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of eclampsia
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Rate of cesarean delivery
Description
Adverse maternal outcomes will be abstracted from medical records, and analyzed using logistic regression with consideration of a history of these conditions.
Time Frame
Through study completion, an average of 2 years
Title
Neonatal adiposity
Description
Percent of total mass that is fat mass, as measured by air displacement plethysmography using the PEA POD device
Time Frame
At birth
Title
Maternal adiposity
Description
Percent of total mass that is fat mass, as measured by air displacement plethysmography using the BOD POD device
Time Frame
Baseline
Title
Maternal adiposity
Description
Percent of total mass that is fat mass, as measured by air displacement plethysmography using the BOD POD device
Time Frame
6-8 weeks gestation
Title
Infant birthweight
Description
Medical records
Time Frame
At birth
Title
Rate of macrosomia
Description
Infant birthweight >4000g. Abstracted from medical records
Time Frame
At birth
Title
Rate of infants classified as large for gestational age (LGA)
Description
Infant birthweight >90th percentile. Abstracted from medical records
Time Frame
At birth
Title
Rate of infants classified as small for gestational age
Description
Infant birthweight <10th percentile. Abstracted from medical records
Time Frame
At birth
Title
Rate of infants with low birthweight
Description
Infant birthweight <2500g. Abstracted from medical records
Time Frame
At birth
Title
Instances of fetal growth restriction
Description
Abstracted from medical records
Time Frame
At birth
Title
Rate of infant birth trauma
Description
Abstracted from medical records
Time Frame
At birth
Title
Rate of infant shoulder dystocia
Description
Abstracted from medical records
Time Frame
At birth
Title
Rate of infant intensive care admission
Description
Abstracted from medical records
Time Frame
At birth
Title
Rate of infants with a major congenital anomaly
Description
Abstracted from medical records
Time Frame
At birth
Title
Rate of neonatal hypoglycemia requiring treatment
Description
Abstracted from medical records
Time Frame
At birth

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
39 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Established patient at Denver Health Biologically female (inclusive of all gender identities) Aged 18-39 years English- or Spanish-speaking BMI ≥25 kg/m2 (≥23 kg/m2 if Asian race) Activities that lead to pregnancy in past 3 months Interested in pregnancy within 24 months, including: High interest (actively trying to conceive) General interest (not actively trying but wanting to become pregnant in the foreseeable future) Neutral interest (not planning pregnancy or using contraception for religious reasons) Exclusion Criteria: Currently pregnant Non-gestational diabetes (type 1, type 2) Long-acting contraceptives (intrauterine device, implant, injection) with plans to continue for >1 year (barrier & short-acting hormonal contraception permitted given ease of discontinuing to facilitate pregnancy) Medical procedures (e.g., tubal ligation, hysterectomy) or conditions that impede pregnancy (e.g., polycystic ovarian syndrome) Documented infertility or unsuccessfully trying to conceive for ≥12 months Prior participation in the NDPP
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Study Coordinator
Phone
720-957-5161
Email
nextgen@cuanschutz.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Katherine Sauder, PhD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

We'll reach out to this number within 24 hrs